RCUS vs. IONS, OGN, BBIO, CYTK, APLS, MDGL, ALPN, NUVL, ALKS, and CRNX
Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Madrigal Pharmaceuticals (MDGL), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical preparations" industry.
Ionis Pharmaceuticals (NASDAQ:IONS) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Arcus Biosciences has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Ionis Pharmaceuticals has a net margin of -49.49% compared to Ionis Pharmaceuticals' net margin of -97.47%. Ionis Pharmaceuticals' return on equity of -40.98% beat Arcus Biosciences' return on equity.
In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Arcus Biosciences. MarketBeat recorded 8 mentions for Ionis Pharmaceuticals and 4 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 0.87 beat Ionis Pharmaceuticals' score of 0.76 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.
Ionis Pharmaceuticals received 496 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 64.54% of users gave Arcus Biosciences an outperform vote while only 60.16% of users gave Ionis Pharmaceuticals an outperform vote.
93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ionis Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
Ionis Pharmaceuticals presently has a consensus target price of $59.54, indicating a potential upside of 58.47%. Arcus Biosciences has a consensus target price of $41.25, indicating a potential upside of 173.72%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Arcus Biosciences is more favorable than Ionis Pharmaceuticals.
Summary
Ionis Pharmaceuticals beats Arcus Biosciences on 10 of the 19 factors compared between the two stocks.
Get Arcus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arcus Biosciences Competitors List
Related Companies and Tools
